Monte Rosa Therapeutics Inc. Common Stock (GLUE)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a price below intrinsic value. Monte Rosa Therapeutics does not fit that mold. It is a clinical-stage biotechnology company with 173 employees, developing molecular glue degraders. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $9.0M and net loss was $43.4M. In fiscal Q1 2026, revenue was $4.2M and net loss was $44.5M. Full-year fiscal 2025 revenue was $123.7M with a net loss of $38.6M; fiscal 2024 revenue was $75.6M with a net loss of $72.7M; fiscal 2023 had no reported revenue and a net loss of $135.4M. So the company has never earned a profit, and FairStock's Lynch category is none because it lost money in each of the last four years. At the 2026-10-13 close of $9.89, market value was $843.7M. FairStock calculations show a negative P/E of -5.65, P/B of 1.73, ROE of -42.66%, ROCE of -21.63%, trailing free cash flow of -$32.1M, and FCF yield of -3.8%. Debt is low with D/E of 0.08, but low debt does not neutralize cash burn. The Piotroski F-Score is 2/9 and Altman Z-Score is 2.11, both weak signals. The business may have scientific promise in MYC-driven tumors and autoimmune/inflammatory disease, but I see no durable competitive moat or proven earning power. A Graham-style investor would demand a margin of safety in assets or earnings; here the value depends on binary clinical outcomes and future financing. This is speculation, not a value bargain.

In plain English: Monte Rosa Therapeutics is a small healthcare company testing new medicines that use small molecules to break down disease-related proteins. It has lost money in each of the last four years, and in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $9.0 million while net loss was $43.4 million. Because it has no steady profits, the $9.89 share price at the 2026-10-13 close is not clearly cheap or expensive from current numbers; it mostly reflects hope for future drug results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer